Risks of breast and endometrial cancer after estrogen and estrogen-progestin replacement

Cancer Causes and Control

Volumn 10, Issue 4, 1999, Pages 253-260

  Persson, Ingemar ^a   Weiderpass, Elisabete ^a   Bergkvist, Leif ^a   Bergström, Reinhold ^a,b   Schairer, Catherine ^c  

^a KAROLINSKA INSTITUTE   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Breast neoplasms; Cohort; Endometrial neoplasms; Estrogens; Hormone replacement therapy; Progestins

Indexed keywords

ESTROGEN; GESTAGEN;

ARTICLE; BREAST CANCER; CANCER REGISTRY; CANCER RISK; ENDOMETRIUM CANCER; ESTROGEN THERAPY; FEMALE; HORMONE SUBSTITUTION; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; QUESTIONNAIRE; SWEDEN;

BREAST NEOPLASMS; COHORT STUDIES; ENDOMETRIAL NEOPLASMS; ESTROGENS; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; MIDDLE AGED; PROGESTINS; QUESTIONNAIRES; RISK FACTORS; SWEDEN;

EID: 0032772686     PISSN: 09575243     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008909128110     Document Type: Article

References (34)

1. Daly E, Gray A, Barlow D, McPherson K, Roche M, Vessey M (1993) Measuring the impact of menopausal symptoms on quality of life. BMJ 307: 836-840.
2. Cummings SR, Kelsey JL, Nevitt MC, O'Dowd KJ (1985) Epidemiology of osteoporosis and osteoporotic fractures. Epidemiol Rev 7: 178-208.
3. Stampfer MJ, Colditz GA (1991) Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence. Prev Med 20: 47-63.
4. Bergkvist L, Adami HO, Persson I, Hoover R, Schairer C (1989) The risk of breast cancer after estrogen and estrogen-progestin replacement. N Engl J Med 321: 293-297.
5. Yang CP, Daling JR, Band PR, Gallagher RP, White E, Weiss NS (1992) Noncontraceptive hormone use and risk of breast cancer. Cancer Causes Control 3: 475-479.
6. Ewertz M (1988) Influence of non-contraceptive exogenous and endogenous sex hormones on breast cancer risk in Denmark. Int J Cancer 42: 832-838.
7. Hunt K, Vessey M, McPherson K, Coleman M (1987) Long-term surveillance of mortality and cancer incidence in women receiving hormone replacement therapy. Br J Obstet Gynaecol 94: 620-635.
8. Colditz GA, Hankinson SE, Hunter DJ, et al. (1995) The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med 332: 1589-1593.
9. Mills PK, Beeson WL, Phillips RL, Fraser GE (1989) Prospective study of exogenous hormone use and breast cancer in Seventh-day Adventists. Cancer 64: 591-597.
10. Persson I, Yuen J, Bergkvist L, Schairer C (1996) Cancer incidence and mortality in women receiving estrogen and estrogen-progestin replacement therapy long-term follow-up of a Swedish cohort. Int J Cancer 67: 327-332.
11. Collaborative Group on Hormonal Factors in Breast Cancer (1997) Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52 705 women with breast cancer and 108 411 women without breast cancer. Lancet 350: 1047-1059.
12. Persson I, Thurfjell E, Bergström R, Holmberg L (1997) Hormone replacement therapy and the risk of breast cancer. Nested case-control study in a cohort of Swedish women attending mammography screening. Int J Cancer 72: 758-761.
13. Newcomb PA, Longnecker MP, Storer BE, et al. (1995) Long-term hormone replacement therapy and risk of breast cancer in postmenopausal women. Am J Epidemiol 142: 788-795.
14. Stanford JL, Weiss NS, Voigt LF, Daling JR, Habel LA, Rossing MA (1995) Combined estrogen and progestin hormone replacement therapy in relation to risk of breast cancer in middle-aged women. JAMA 274: 137-142.
15. Schuurman AG, van den Brandt PA, Goldbohm RA (1995) Exogenous hormone use and the risk of postmenopausal breast cancer: results from The Netherlands Cohort Study. Cancer Causes Control 6: 416-424.
16. Schairer C, Byrne C, Keyl PM, Brinton LA, Sturgeon SR, Hoover RN (1994) Menopausal estrogen and estrogen progestin replacement therapy and risk of breast cancer (United States). Cancer Causes Control 5: 491-500.
17. Grady D, Gebretsadik T, Kerlikowske K, Ernster V, Petitti D (1995) Hormone replacement therapy and endometrial cancer risk: a meta-analysis. Obstet Gynecol 85: 304-313.
18. Shapiro JA, Weiss NS, Beresford SA, Voigt LF (1998) Menopausal hormone use and endometrial cancer, by tumor grade and invasion. Epidemiology 9: 99-101.
19. Brinton LA, Hoover RN (1993) Estrogen replacement therapy and endometrial cancer risk: unresolved issues. The Endometrial Cancer Collaborative Group. Obstet Gynecol 81: 265-271.
20. Persson I, Adami HO, Bergkvist L, et al. (1989) Risk of endometrial cancer after treatment with oestrogens alone or in conjunction with progestogens: results of a prospective study. BMJ 298: 147-151.
21. Voigt LF, Weiss NS, Chu J, Daling JR, McKnight B, van Belle G (1991) Progestagen supplementation of exogenous oestrogens and risk of endometrial cancer. Lancet 338: 274-277.
22. Jick SS, Walker AM, Jick H (1993) Estrogens, progesterone, and endometrial cancer. Epidemiology 4: 20-24.
23. Beresford SA, Weiss NS, Voigt LF, McKnight B (1997) Risk of endometrial cancer in relation to use of oestrogen combined with cyclic progestagen therapy in postmenopausal women. Lancet 349: 458-461.
24. Pike MC, Peters RK, Cozen W, et al. (1997) Estrogen-progestin replacement therapy and endometrial cancer. J Natl Cancer Inst 89: 1110-1116.
25. Persson I, Adami HO, Johansson E, Lindberg B, Manell P, Westerholm B (1983) Cohort study of oestrogen treatment and the risk of endometrial cancer: evaluation of method and its applicability. Eur J Clin Pharmacol 25: 625-632.
26. National Board of Health and Welfare. Stockholm (1996) Official Statistics of Sweden.
27. MCullagh P, Nelder J (1989) In: MCullagh P, Nelder J, eds Generalized Linear Models. London: Chapman & Hall.
28. Persson I, Bergkvist L, Lindgren C, Yuen J (1997) Hormone replacement therapy and major risk factors for reproductive cancers, osteoporosis, and cardiovascular diseases: evidence of confounding by exposure characteristics. J Clin Epidemiol 50: 611-618.
29. Nyström L, Rutqvist LE, Wall S, et al. (1993) Breast cancer screening with mammography: overview of Swedish randomised trials. Lancet 341: 973-978.
30. Persson I, Thurfjell E, Holmberg L (1997) Effect of estrogen and estrogen-progestin replacement regimens on mammographic breast parenchymal density. J Clin Oncol 15: 3201-3207.
31. Laya MB, Larson EB, Taplin SH, White E (1996) Effect of estrogen replacement therapy on the specificity and sensitivity of screening mammography. J Natl Cancer Inst 88: 643-649.
32. Pike MC, Spicer DV, Dahmoush L, Press MF (1993) Estrogens, progestogens, normal breast cell proliferation, and breast cancer risk. Epidemiol Rev 15: 17-35.
33. Key TJ, Pike MC (1988) The dose-effect relationship between "unopposed" oestrogens and endometrial mitotic rate: its central role in explaining and predicting endometrial cancer risk. Br J Cancer 57: 205-212.
34. Cline JM, Söderqvist G, von Schoultz E, Skoog L, von Schoultz B (1996) Effects of hormone replacement therapy on the mammary gland of surgically postmenopausal cynomolgus macaques. Am J Obstet Gynecol 174: 93-100.